title: Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapy.
abstract: Approximately 20%-40% of patients with small-volume residual ovarian cancer, following systemically administered platinum-based chemotherapy, will respond to a second-line intraperitoneal treatment regimen. In an effort to improve the selection criteria for patients being considered for this regional therapeutic approach, we retrospectively evaluated the influence of pretreatment CA-125 levels on the ability of a group of 70 patients with small-volume residual ovarian cancer (no tumor mass greater than 1 cm in diameter) to achieve a surgically defined complete response (S-CR) following treatment on one of three phase-2 intraperitoneal chemotherapy trials conducted at the Memorial Sloan-Kettering Cancer Center. Overall, 18/46 (39%) patients with normal pretreatment CA-125 levels (less than or equal to units/ml) achieved a S-CR, compared to only 4/24 patients (17%) with an elevated pretreatment value (chi 2 = 3.7, P greater than 0.5). Despite the lower S-CR rate in patients with elevated CA-125 levels, the duration of response and survival were similar in the two patient populations achieving a S-CR. Thus, we conclude that an elevated pretreatment CA-125 level in a patient with small-volume residual ovarian cancer should not be used by itself to disqualify an individual from consideration for a second-line intraperitoneal treatment regimen, although the finding suggests a reduced likelihood of achieving a S-CR with this therapeutic approach.
authors.affiliation: Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
authors.forename: M
authors.initials: M
authors.lastname: Markman
authors.forename: B
authors.initials: B
authors.lastname: Reichman
authors.forename: T
authors.initials: T
authors.lastname: Hakes
authors.forename: J
authors.initials: J
authors.lastname: Curtin
authors.forename: R
authors.initials: R
authors.lastname: Barakat
authors.forename: S
authors.initials: S
authors.lastname: Rubin
authors.forename: W
authors.initials: W
authors.lastname: Jones
authors.forename: J L
authors.initials: JL
authors.lastname: Lewis
authors.forename: L
authors.initials: L
authors.lastname: Almadrones
authors.forename: W
authors.initials: W
authors.lastname: Hoskins
mesh_terms: D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D000970:Antineoplastic Agents / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007274:Injections, Intraperitoneal; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D000970:Antineoplastic Agents